Skip to content

Your cart is empty

Continue shopping

Have an account?

Log in to check out faster.

Your cart

Loading...

Estimated total

$0.00 USD

Taxes, discounts and shipping calculated at checkout

Membership enrollment is open. Bloodwork, protocol and provider care in one plan.HSA / FSA eligible. Drawn at Quest near you.See membership
eūvita Health
  • Your Goals
    • Hormone Health
    • Metabolic Health
    • Body Composition
    • Cognitive Performance
    • Longevity & Recovery
    • Skin Care
    • Functional Medicine
  • Lab Testing
  • Shop
    • Memberships
    • All products
    • Men
    • Women
    • Supplements
  • About
    • eūvita Medical
    • Partners
    • Press
  • Portal
Cart Get StartedGet Started
  • Your Goals
    • Hormone Health
    • Metabolic Health
    • Body Composition
    • Cognitive Performance
    • Longevity & Recovery
    • Skin Care
    • Functional Medicine
  • Lab Testing
  • Shop
    • Memberships
    • All products
    • Men
    • Women
    • Supplements
  • About
    • eūvita Medical
    • Partners
    • Press
  • Portal
  • Log in
Legal Center

Legal Center

Terms & ConditionsPrivacy PolicyConsumer Health Data Privacy PolicyHIPAA Notice of Privacy PracticesTelehealth Informed ConsentSMS / Text Message Terms of ServiceCalifornia Notice at CollectionYour Privacy ChoicesReturn & Refund PolicyWhole Health Membership AgreementWeight Protocol Membership AgreementHormone Protocol Membership AgreementNY/NJ Laboratory Billing Addendum
Legal

Important Safety Information: Compounded GLP-1 (semaglutide)

Common effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, most often around a dose change. Serious risks include pancreatitis, gallbladder disease (reported more often than with placebo in trials), kidney injury from dehydration, and hypoglycemia in combination with certain other medications, including insulin and sulfonylureas. FDA-approved semaglutide products carry a boxed warning for thyroid C-cell tumors observed in rodents; human relevance is not established, and semaglutide must not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Diabetic retinopathy complications have been reported, mainly in people with existing retinopathy. Current labeling also calls for monitoring for new or worsening depression or suicidal thoughts, as a precaution rather than a confirmed causal link, discontinue and seek care if these occur.

Contact your care team for persistent severe abdominal pain, ongoing vomiting, vision changes, or any new or worsening mood changes.

Questions about this document? support@euvitahealth.com↑ Back to top
eūvita

Whole health starts with you.

  • (561) 372-4226
  • support@euvitahealth.com
Verify Approval for www.euvitahealth.com
Whole Health
  • How it works
  • BiomarkerIQ
Services
  • Fitness counseling
  • Nutritional counseling
  • Membership
  • Our approach
Company
  • About eūvita
  • Member Portal
Legal
  • Terms & Conditions
  • Privacy Policy
  • Consumer Health Data Privacy
  • HIPAA Notice of Privacy Practices
  • Telehealth Informed Consent
  • SMS Terms
  • California Notice at Collection
  • Return & Refund Policy

eūvita is a telehealth platform. Medical services are provided by Euvita Medical Group PLLC and its licensed providers. Prescription products, including hormone and peptide protocols, require an evaluation with a licensed clinician who will determine whether a prescription is appropriate. Compounded products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Lab results alone are not intended to diagnose any condition. Individual results vary. Product and service availability varies by state.

© 2026 eūvita Health. All rights reserved.

  • Choosing a selection results in a full page refresh.
  • Opens in a new window.